InvestIdeas

On hindsight, I should have stack up re. HALO. It is a very close proxy shares to collect alongside OCUL. ie. HALO gap of 14 was closed.

Picked up a few OCUL below 10$ today.
The CEO news (not that negative, imo) and the MS downgrade should be priced in by now.
And the 19th is getting closer.

investar wrote:Picked up a few OCUL below 10$ today.
The CEO news (not that negative, imo) and the MS downgrade should be priced in by now.
And the 19th is getting closer.

WOW you are very gutty. I was tempted to pick up at 9-ish but didn't ...

Am anxious. coz more puts to calls ratio now. on e bet if e approval is on time? ... or insiders already knew of e immenient regulatory delay due to e site audit enquiry. Insti fund stands lower at 65%. Last night Vol spiked however was not sustainable hence a spinning top was formed (rested onto its 14 days MA). Shall check on e Puts Options tonight/ tomorrow. Last night someone made a mistake bought $11 of 30k shares market instead of limit price; Vol is not comparable to its Conference days earlier ... And even after FDA approval, remember it'll be competing in a crowded market, so nothing to get excited about, Market cap $300M ~ $450M. Plus some recent critics/Twitter sentiments re. intracanalicular insert infection arising ...

Looking for a new subsitute momentum play after $OCUL exit. Ah. I admitted I do like $HALO better (yes strong partnerships) P1,1b,& 2 out w/o report of cardiac effects via $HALO PegpH20 platform and it shall be closely watched now ...

Re. OCUL. I got caught in e warzone of shorts activists and unable to be out. Think by now the paperloss is USD $5k thereof discounting e fact of various swings at my first entry at 8-ish. Its historic lowest was 4.04 and when the Dextenza failed e PhIII trial was 6.30. premarket gap is now around 6-ish on Monday (by now, multiple lawsuits were filed on behalf of ocul). If you read the seekingalpha article published two days ago, the shorts activists seemed to have a fair point re. Manufacturing issue and e batches used in the CT. Consistency of manufactured batches were not there, producing in small amount and precipitation issues.

NOW the dilemma is if I should cut loss or join the shorts???

Re. OCUL. Am still vested. The company has filed a response yesterday closing session, hence gap up to 7-ish pre-market (likely close the gap of 9). I regretted not protecting my position with an amulet of a Put option underlying the stock. However this is a learning experience and an eye-opener knowing that any biotech stocks might get raided by activists and shorts.

As the manufacturing information and response etc are not obligated public information nor publication unlike clinical trials information. Henceforth it is hard for us to track the actual crisis following the order of logics. If a product is new way of manufacturing and had eqpt issue or aka. particulates are not contaminated products, hence if one is not strong on technical manufacturing knowledge will be swayed by the shortists.

Ocul request for new FDA date on 19 Oct. Now the response says no expected site reinspection ..... We shall see what happens next ....

CUT ALL LOSSES and sold OCUL @ 6.05 because management is no longer seen as credible ... Too amateurish to handle the CRL, and likely raise more cash to resolve fraud cases and change its plant/ eqpt, plus may also incur consultant costs to extensively lobby FDA now. ALL will cost $$$. Wait till its earning quarter on 06 Aug.

OCUL, still holding shares (unfortunately the news caught me off guard), the summer not so bright for this stock

Yesterday new coverage, Buy and PT 10$, but no reaction

https://www.benzinga.com/stock/ocul/ratings